The cysteinyl-leukotrienes (cysLTs) LTC 4 , LTD 4 , and LTE 4 , are involved in a variety of inflammatory diseases, including asthma, and act on at least two distinct receptors, CysLT 1 and CysLT 2 . Specific antagonists of CysLT 1 are currently used to control bronchoconstriction and inflammation in asthmatic patients. The potential role of CysLT 2 in asthma remains poorly understood. A polymorphism in the CysLT 2 gene, resulting in a single amino acid substitution (M201V), was found to be associated with asthma in three separate population studies. Here, we investigated whether the M201V mutation affected the affinity of CysLT 2 for its natural ligands and its signaling efficiency. Human embryonic kidney 293 cells were stably transfected with either wild-type (wt) or mutant (M201V) CysLT 2 . Affinity of the M201V receptor for LTC 4 was reduced by 50%, whereas affinity for LTD 4 was essentially lost. LTC 4 -induced production of inositol phosphates (IPs) in M201V-expressing cells was significantly decreased at suboptimal concentrations of the ligand, but no difference was observed at high concentrations. In contrast, LTD 4 -induced IP production was 10-to 100-fold less in M201V-than in wt-expressing cells. Similar results were also observed with the transactivation of the interleukin-8 promoter induced by LTC 4 or LTD 4 . Moreover, in contrast to wt-expressing cells, phosphorylation of nuclear factor B p65 was absent in LTD 4 -stimulated M201V-expressing cells. Likewise, phosphorylation of c-Jun N-terminal kinase was not induced in LTD 4 -stimulated M201V cells, whereas activation of extracellular response kinase and p38 was maintained, at least at higher LTD 4 concentrations. Our results indicate that the M201V polymorphism drastically affects CysLT 2 responses to LTD 4 and less to LTC 4 .
Introduction
Cysteinyl-leukotrienes (cysLTs), which include LTC 4 , LTD 4 , and LTE 4 , are lipid mediators of inflammation, derived from arachidonic acid through the 5-lipoxygenase pathway (Samuelsson, 1983) . They are involved in a variety of inflammatory diseases, such as asthma and allergic rhinitis and are produced mainly by leukocytes (eosinophils, mast cells, etc.) and endothelial cells (Folco and Murphy, 2006; Jiang et al., 2007) .
CysLTs act on at least two distinct G protein-coupled receptors (GPCRs), namely CysLT 1 and CysLT 2 . These receptors share only 38% homology in amino acid sequence (Lynch et al., 1999; Sarau et al., 1999; Heise et al., 2000; Nothacker et al., 2000; Takasaki et al., 2000) . CysLT 1 is abundantly expressed in human lung smooth muscle cells and peripheral blood monocytes and eosinophils (Figueroa et al., 2001) . The rank order affinity of cysLTs for CysLT 1 was reported as LTD 4 Ͼ LTC 4 Ͼ Ͼ LTE 4 , and this receptor is coupled mainly to G␣ q . Specific antagonists of CysLT 1 , such as montelukast, zafirlukast, and pranlukast, are currently used to control bronchoconstriction and inflammation in asthmatic patients (Sarau et al., 1999; Bä ck, 2002) .
The CysLT 2 receptor may also be involved in asthma, although its role and signaling remain poorly understood. Its implication in a number of inflammatory diseases has been suggested in several studies (Lotzer et al., 2003; Beller et al., 2004; Hui et al., 2004; Rovati and Capra, 2007) . Furthermore, the gene encoding for the CysLT 2 receptor is localized on chromosome 13q14 near a locus associated with atopic asthma (Heise et al., 2000) . However, specific CysLT 2 recep-tor antagonists have not been developed as yet, but a leukotriene analog, 4-[[(1R,2E,4E,6Z,9Z)-1-[(1S)-4-carboxy-1-hydroxybutyl]-2,4,6,9-pentadecatetraenyl]thio]-benzoic acid (BAY u9773) , is a weak dual CysLT 1 /CysLT 2 antagonist that is also a partial agonist of CysLT 2 (Nothacker et al., 2000; Thompson et al., 2003) . The rank order affinity of cysLTs for CysLT 2 is LTC 4 ϭ LTD 4 Ͼ Ͼ LTE 4 , as demonstrated by binding studies (Heise et al., 2000; Nothacker et al., 2000; Takasaki et al., 2000) . The highest levels of mRNA expression of CysLT 2 were reported in interstitial lung macrophages, peripheral blood leukocytes, heart, adrenal gland, central nervous system, and placenta.
CysLT 2 mRNA and protein expression can be regulated by cytokines. The expression is up-regulated by the T helper 2 cytokine IL-4 in mast cells and human umbilical vein endothelial cells and down-regulated by tumor necrosis factor ␣ and IL-1␤ (Lotzer et al., 2003; Mellor et al., 2003) . In addition, in eosinophils, CysLT 2 expression can be up-regulated by interferon ␥ (Fujii et al., 2005) . The activation of CysLT 2 was reported to play a role in inflammation, thrombosis, and atherosclerosis . CysLT 2 is coupled mainly to G␣ q but also to G␣ i (Mellor et al., 2003; Uzonyi et al., 2006) . LTC 4 and LTD 4 seem to be equipotent in terms of calcium mobilization when acting on CysLT 2 (Nothacker et al., 2000) . CysLT 2 signaling can also induce the activation of genes such as IL-8, P-selectin, and CXC chemokine ligand 2 (McIntyre et al., 1986; Pedersen et al., 1997; Uzonyi et al., 2006; Thompson et al., 2008) . IL-8 is a cytokine/chemokine implicated in inflammation, and its major role resides in the recruitment and activation of neutrophils (Harada et al., 1994) . Its promoter region is well characterized and contains several transcription sites, including binding sequences for NF-B, AP-1, and NF-IL-6, which can control the regulation of IL-8 expression (Hoffmann et al., 2002) . We have shown previously that NF-B and AP-1 were necessary for induction of IL-8 promoter transactivation and protein synthesis when CysLT 2 was activated by LTC 4 (Thompson et al., 2008) .
It is noteworthy that a polymorphism in the CysLT 2 gene, resulting in a single amino acid substitution (M201V), was found in three separate population studies. First, the M201V CysLT 2 variant has been observed in the Tristan da Cunha population to be associated with atopy (Thompson et al., 2003) . In another study, the CysLT 2 variant has been reported to be associated with asthma in a white and an African-American population (Pillai et al., 2004) . Those two articles also demonstrated that the M201V polymorphism decreased responsiveness to LTD 4 in terms of calcium mobilization.
We hypothesized that the M201V mutation could affect the affinity of CysLT 2 for its natural ligands and/or its signaling efficiency. We thus investigated the affinity of wild-type (wt) and mutant (M201V) CysLT 2 for LTC 4 and LTD 4 and the signaling events that were induced by ligand stimulation, using human embryonic kidney (HEK) 293 cells stably transfected with either wt or mutant CysLT 2 . Our results indicate that the M201V polymorphism drastically reduces CysLT 2 responses to LTD 4 , more than to LTC 4 , and affects selective signaling pathways. Plasmids. pIRESpuro3a-cmyc-CysLT2wt or pIRESpuro3a-cmycCysLT2M201V encoding for cMyc-labeled human CysLT 2 wt receptor or cMyc-labeled human CysLT 2 M201V receptor were puromycin resistant (under the control of a cytomegalovirus promoter) and were constructed in our laboratory. The human IL-8 promoter luciferase construct hIL-8/luc (Ϫ162/ϩ44) was a kind gift from Dr. Allan R. Brasier (University of Texas Medical Branch, Galveston, TX) and was used as described by Thompson et al. (2008) .
Materials and Methods

Materials
Cells. HEK293 cells (American Type Culture Collection) were cultured in DMEM with high glucose, supplemented with 5% fetal bovine serum, penicillin (100 g/ml), and streptomycin (100 g/ml). Transient transfections were carried out with TransIT-LT1, and experiments were performed 48 h after transfection.
HEK-293 Stably Expressing CysLT 2 wt or CysLT 2 M201V. HEK-293 cells were stably transfected with pIRESpuro3a-cmycCysLT2wt or pIRESpuro3a-cmyc-CysLT2M201V (1 g of linearized DNA) using TransIT-LT1 (3 l). Forty-eight hours after transfections, puromycin was added at a final concentration of 10 g/ml. Cells were then cultured until 100% confluence in medium containing puromycin and isolated for clonal selection. Cell clones were analyzed for cMyc expression by FACScan flow cytometer (BD Biosciences, San Jose, CA). Positive clones were maintained in 10 g/ml puromycin and referred to as CysLT 2 wt or CysLT 2 M201V. For adequate comparison in our studies, clones expressing equivalent levels of wt or M201V CysLT 2 were used.
Radioligand Binding Assays. When CysLT 2 wt and CysLT 2 M201V cells were near 100% of confluence, they were harvested and used for the binding assays. For saturation binding assays, cells (750,000 cells) were incubated in the buffer (Tris, pH 7.4, 10 mM CaCl 2 , 10 mM MgCl 2 , 10 mM glycine, 10 mM cysteine, and 0.1% bovine serum albumin) with 0.1 to 12 nM [ 3 H]LTC 4 or 0.1 to 15 nM [ 3 H]LTD 4 for 1 h at 25°C. After incubation, cells were washed by the addition of buffer followed by a spin to remove the nonspecific radioactivity. After three washes, cells were added to a liquid scintillation ␤-counter (LKB-Wallac) to measure the radioactivity. Nonspecific binding was determined in the presence of 2 M unlabeled LTC 4 or LTD 4 . LTC 4 or LTD 4 -specific binding was calculated by subtracting nonspecific binding from total binding. Data were analyzed by nonlinear transformation analysis using Prism software (GraphPad Software, Inc., San Diego, CA).
Inositol Phosphate Production Assays. CysLT 2 wt and CysLT 2 M201V cells were labeled with [ 3 H]myo-inositol in DMEM without inositol for 16 h. The next day, cells were incubated in DMEM, 0.1% bovine serum albumin, and 20 mM LiCl for 10 min and then stimulated for 45 min with LTC 4 , LTD 4 , or EtOH at the indicated concentrations. The reactions were terminated by the addition of cold perchloric acid and after an incubation of 30 min on ice, inositol phosphates (IPs) were extracted and separated on Dowex AG 1-X8 columns. Total labeled IPs were then counted by liquid scintillation in an LKB-Wallac ␤-counter.
Luciferase Assays. CysLT 2 wt and CysLT 2 M201V cells were plated in 12-well tissue culture plates for 24 h. The cells were then transfected with 25 ng of IL-8 WT/luc or empty vector per well, using 0.75 l of TransIT-LT1 transfection reagent. After 24 h, cells were serum-starved overnight before stimulation with LTC 4 , LTD 4 , or EtOH for 6 h. Cell lysates were assayed for luciferase activity using the Dual-Glo luciferase system (Promega, Madison, WI).
Western Blot Analysis. This assay was carried out as described by Thompson et al. (2008) . In brief, CysLT 2 wt and CysLT 2 M201V cells in six-well plates were incubated in medium with 0.2% serum for 16 h and stimulated with LTC 4 , LTD 4 or EtOH for the indicated times or concentrations. Stimulated cells were lysed in buffer [10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM EGTA, 5% sodium deoxycholate, 10% Triton X-100, 10 mM NaF, 100 g/ml 4-(2-aminoethyl)benzenesulfonyl fluoride, 1 g/ml leupeptin, 2 g/ml aprotinin, 10 g/ml soybean trypsin inhibitor, 1 mM Na 3 VO 4 , 1 nM Calyculin A, and 15 nM okadaic acid] for 30 min on ice. Lysates were separated on 8 or 10% SDS-polyacrylamide gel electrophoresis and transferred to Trans-Blot nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA). After blocking and incubation with specific antibodies overnight, membranes were washed and incubated with horseradish peroxydase-labeled secondary antibodies. For protein detection, enhanced chemiluminescence detection was used (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK). Signal intensity was quantitated by densitometry (Epson Expression 1680 scanner; Epson America, Torrance, CA) and analyzed using Image J 1.38X software (National Institutes of Health, Bethesda, MD). After detection, membranes were stripped, washed, and used with the appropriate antibodies for detect total proteins. Statistical Analyses. Statistical significance was assessed using Student's t test or two-way ANOVA with Bonferroni post-tests, as appropriate, using Prism 5.0 (Graph Pad Software Inc.). Differences were considered significant at p Յ 0.05. (Fig. 1, C and D) . These results suggest that the M201V mutation affects particularly the affinity of the CysLT 2 receptor for LTD 4 in spite of equivalent amounts of CysLT 2 receptor protein expressed in the wt and mutant cell lines.
Results
Expression of CysLT
Inositol Phosphate Production in CysLT 2 wt and CysLT 2 M201V Cells. The M201V variant was shown to respond to LTD 4 5-fold less than the wt receptor in terms of calcium mobilization (Thompson et al., 2003; Pillai et al., 2004) . To assess whether this was associated with a reduction in IP production, CysLT 2 wt or CysLT 2 M201V cells were stimulated for 45 min with graded concentrations of LTC 4 or LTD 4 . As shown in Fig. 2 , both LTC 4 and LTD 4 induced IP production in a concentration-dependent manner in CysLT 2 wt cells. It is noteworthy that LTC 4 was more potent than LTD 4 . In CysLT 2 M201V cells, LTC 4 also induced an IP production in a concentration-dependent manner ( Fig. 2A) . However, this production was significantly decreased at lower (1 and 10 nM) concentrations and became equivalent to that of CysLT 2 wt cells at 100 nM LTC 4 . In contrast, LTD 4 induced only very low IP production and only at 100 nM (Fig. 2B) .
IL-8 Promoter Activity in CysLT 2 wt or CysLT 2 M201V Cells. In a previous study, LTC 4 and LTD 4 had been shown to up-regulate IL-8 gene expression and protein synthesis in HEK293 cells transfected with CysLT 2 wt (Thompson et al., 2008) . To investigate the effects of the M201V mutation on IL-8 promoter activity, CysLT 2 wt or CysLT 2 M201V cells were transfected with a luciferase reporter gene driven by the IL-8 promoter and stimulated with LTC 4 or LTD 4 , and the luciferase activity was then measured. As shown in Fig. 3A , LTC 4 induced IL-8 transactivation in a concentration-dependent manner in CysLT 2 wt cells after a stimulation of 6 h. In these cells, LTD 4 also up-regulated IL-8 promoter activity (Fig. 3B) . It is noteworthy that, as with IP production, LTC 4 was more potent than LTD 4 and induced an equivalent level of IL-8 promoter transactivation at 10-fold lower concentrations. As shown in Fig. 3A , LTC 4 also induced a concentration-dependent IL-8 transactivation in CysLT 2 M201V cells. However, this promoter activity was significantly decreased at lower concentrations of LTC 4 and became equivalent to that of the wt receptor only at 100 nM. Finally, LTD 4 induced very little IL-8 transactivation in CysLT 2 M201V cells and only at a concentration of 100 nM in these cells (Fig. 3B) .
NF-B Pathway Activation in CysLT 2 wt or CysLT 2 M201V Cells. Because LTC 4 -induced IL-8 promoter activity had been shown to involve mainly NF-B and AP-1 binding sites (Thompson et al., 2008) , we tested whether p65 phosphorylation would be differentially induced in CysLT 2 wt and M201V cells. As shown in Fig. 4A , LTC 4 at 10 nM induced a time-dependent p65 phosphorylation in CysLT 2 wt cells, with a maximal induction at 15 min. Similar results were observed with LTD 4 at 100 nM in CysLT 2 wt cells (Fig. 4B) . Furthermore, LTC 4 and LTD 4 produced a concentration-dependent phosphorylation of the p65 in CysLT 2 wt cells with maximal activation at 100 nM (Fig. 4, C and D) . In CysLT 2 M201V cells, LTC 4 induced p65 phosphorylation at 15 min, but it was significantly lower than in CysLT 2 wt cells (Fig. 4,  A and C 4C). In contrast, LTD 4 failed to activate the p65 NF-B subunit in CysLT 2 M201V cells at all times and concentrations used (Fig. 4, B-D) . MAPK Pathway Activation in CysLT 2 wt or CysLT 2 M201V Cells. Because of the implication of AP-1 in IL-8 transactivation, we studied the activation of MAPK pathway elements by CysLT 2 wt and CysLT 2 M201V. As illustrated in Fig. 5A , LTC 4 induced a time-dependent ERK phosphorylation with a maximal induction at 5 min in CysLT 2 wt cells. This activation of ERK by LTC 4 was concentration-dependent in CysLT 2 wt cells and was maximal at 10 to 100 nM (Fig. 6A) . In these cells, LTD 4 induced a more protracted ERK phosphorylation (Fig. 5B) , with a maximal stimulation at 10 nM LTD 4 (Fig. 6B) . In CysLT 2 M201V cells, LTC 4 induced also a time-dependent ERK activation with a maximal induction at 5 min (Fig. 5A) . However, this activation decreased more rapidly after 15 min. Similar results were obtained with LTD 4 stimulation in CysLT 2 M201V cells (Fig.  5B ). As shown in Fig. 6A , LTC 4 induced a concentrationdependent ERK phosphorylation in CysLT 2 M201V cells that was similar to the activation in CysLT 2 wt cells, except at 1 nM. As for LTD 4 , stimulation of CysLT 2 M201V cells induced ERK phosphorylation only at 100 nM (Fig. 6B) .
In CysLT 2 wt cells, LTC 4 induced a time-dependent p38 activation with a plateau from 15 to 60 min (Fig. 5C ). LTD 4 also produced a time-dependent p38 activation in CysLT 2 wt cells, with a maximal activation at 15 min (Fig. 5D) . At 15 min, LTC 4 and LTD 4 induced a concentration-dependent p38 phosphorylation that was very similar to that of ERK in CysLT 2 wt cells (Fig. 6, C and D) . In CysLT 2 M201V cells, LTC 4 produced a time-dependent p38 activation with a maximal induction at 15 min (Fig. 5C ). However, this activation was significantly lower at 30 and 45 min compared with that in CysLT 2 wt cells. On the other hand, whereas LTC 4 induced a concentration-dependent p38 phosphorylation in CysLT 2 M201V cells that was similar to that in CysLT 2 wt cells (Fig. 6C) , LTD 4 did not induce a significant p38 phosphorylation in CysLT 2 M201V cells in contrast to that in CysLT 2 wt cells (Figs. 5D and 6D) .
LTC 4 induced a time-dependent JNK phosphorylation in CysLT 2 wt cells with a maximal effect at 30 min (Fig. 5E ). LTD 4 also induced a time-dependent JNK activation with a peak induction at 30 min but it was less pronounced than with LTC 4 (Fig. 5F ). LTC 4 and LTD 4 also induced a concentration-dependent JNK phosphorylation with a maximal activation at 100 nM in CysLT 2 wt cells, with LTC 4 inducing a greater response than LTD 4 at lower concentrations (Fig. 6 , E and F). In CysLT 2 M201V cells, LTC 4 produced a significant time-dependent JNK phosphorylation with a maximal induction at 15 min (Fig. 5E) . However, this effect was significantly decreased at 30 to 60 min compared with CysLT 2 wt cells. On the other hand, LTD 4 failed to induce any significant JNK phosphorylation in CysLT 2 M201V cells at all time points and concentrations used (Figs. 5F and 6F).
Discussion
The M201V polymorphism in the CysLT 2 receptor is predicted to be localized in the C-terminal portion of extracellular loop (ECL) 2, adjacent to transmembrane helix (TM) V. Comparison with available crystal structures of GPCRs (Palczewski et al., 2000; Rasmussen et al., 2007; Warne et al., 2008) indicates that the residues corresponding to Met201 may contact the junction between the end of TM IV and the beginning of ECL2. Moreover, according to this analysis, Met201 would be located in the first helical turn of TM V. Considering that, compared with Met, Val has a shorter and ␤-branched side chain, it is quite possible that the M201V mutation would perturb the local secondary structure, because of its lower propensity for helix formation and/or the tertiary contacts present in the wt receptor. The roles of residues in the ECL of GPCR are not well understood, al- or LTD 4 (B) at 10 nM for LTC 4 and 100 nM for LTD 4 for the indicated times. Total proteins were separated by electrophoresis, and Western blots were performed using the indicated antibodies. Total p65 protein expression was used as internal control. Data are reported as relative intensity of p-p65 over p65 with the CysLT 2 wt response at 15 min set to 100. C and D, concentration-response. Cells were stimulated for 15 min with EtOH and LTC 4 (C) or LTD 4 (D) at the indicated concentrations. Data are reported as relative intensity of p-p65 over p65 with the CysLT 2 wt response at 100 nM set to 100. Lane C, control using EtOH (100 nM). ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001, using two-way ANOVA with Bonferroni post-tests (n ϭ 3-4).
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at ASPET Journals on April 19, 2017 jpet.aspetjournals.org though they seem to be functionally important. In particular, ECL2, which links TM IV and V, has been shown to project into the TM bundle where ligand binding occurs (Palczewski et al., 2000; Li et al., 2004; Shi and Javitch, 2004) . Because ECL2 is known to play an important role in ligand binding in certain receptors (Boucard et al., 2000; Rasmussen et al., 2007; Warne et al., 2008) , a modulation in affinity toward LTC 4 and LTD 4 caused by this mutation is not unexpected. The binding site of cysteinyl leukotrienes to either of their receptors has not been determined. However, it has been shown that LTB 4 , a leukotriene lacking the cysteinyl moiety, uses, when binding to its high-affinity receptor (BLT1), residues in the C-terminal part of the ECL2 and TM5, regions possibly affected by the M201V mutation (Gearing et al., 2003; Sabirsh et al., 2006; Basu et al., 2007) .
In addition to a role in ligand binding, the ECL2 region may have a role in receptor activation. Mutations targeting ECL2 modulate both ligand-dependent and -independent receptor activation (Banères et al., 2005; Klco et al., 2005; Scarselli et al., 2007) . For instance, polar residues within TMs of BLT1 play an important role in signal transduction after ligand-induced conformational changes (Basu et al., 4 and at 100 nM for LTD 4 for the indicated times. Total proteins were separated by electrophoresis, and Western blots were performed using the indicated antibodies. Total ERK (A and B), p38 (C and D), or JNK (E and F) protein expression was used as internal control. Data are reported as relative intensity of phosphorylated protein over total protein with the CysLT 2 wt response at 15 min set to 100. Lane C, control using EtOH (100 nM). ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001, using two-way ANOVA with Bonferroni post-tests (n ϭ 3-4).
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). Moreover, studies of ECL2 of GPCR for small peptides or biogenic amines (e.g., the V1a vasopressin receptor and the M3 muscarinic acetylcholine receptor) revealed the presence of several residues that were important for efficient agonist-induced receptor activation (Conner et al., 2007; Scarselli et al., 2007) . Thus the conformational change in M201V may, in addition to an effect on ligand affinity, modulate the activational capacity of the receptor.
Using HEK293 cells that stably expressed equivalent levels of the CysLT 2 wt or the CysLT 2 M201V receptor, we have shown that the M201V mutation decreased the affinity of the CysLT 2 receptor for LTC 4 by 50% and to an undetectable level for LTD 4 , using tritiated ligands. This polymorphism also affected the signaling efficiency of CysLT 2 . It impaired the production of IPs, the transactivation of the IL-8 promoter, and the phosphorylation of p65, ERK, p38, and JNK. (B, D, and F) at the indicated concentrations. Total proteins were separated by electrophoresis, and Western blots were performed using the indicated antibodies. Total ERK (A and B), p38 (C and D), or JNK (E and F) protein expression was used as internal control. Data are reported as relative intensity of phosphorylated protein over total protein with the CysLT 2 wt response at 100 nM set to 100. Lane C, control using EtOH (100 nM). ‫,ء‬ p Ͻ 0.05; ‫,ءءء‬ p Ͻ 0.001, using two-way ANOVA with Bonferroni post-tests (n ϭ 3-9). 
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CysLT 2 responses to LTD 4 were much more affected than those to LTC 4 , with p65 and JNK signaling pathways being more affected than ERK and p38. The localization of this polymorphism at the junction of ECL2 and TMV of the CysLT 2 receptor may thus be in a position that can alter ligand binding and receptor signaling.
The two groups that initially reported the association of the M201V polymorphism with atopy and asthma found LTD 4 to be 2-to 4-fold less potent in inducing Ca 2ϩ mobilization in cells expressing CysLT 2 M201V compared with CysLT 2 wt (Thompson et al., 2003; Pillai et al., 2004) . Responses to LTC 4 were not decreased, however, but their cells were transiently transfected and levels of expression of the respective receptors were not indicated. Nevertheless, the drastically decreased IP production that we observed in M201V cells in response to LTD 4 correlates well with the reported decrease in Ca 2ϩ mobilization. In addition, however, we found responses to LTC 4 to be reduced at suboptimal concentrations.
IL-8 promoter transactivation was also markedly reduced in CysLT 2 M201V-expressing cells. IL-8 (CXC chemokine ligand 8) is a cytokine/chemokine implicated in inflammation and is associated with several pathologies, including asthma (Harada et al., 1994; Norzila et al., 2000; Ordonez et al., 2000; Gibson et al., 2001) . IL-8 is usually regulated at the transcriptional level through promoter regions that bind NF-B, AP-1, and NF-IL-6 (Hoffmann et al., 2002) . We have previously shown that CysLT 2 activation by LTC 4 or LTD 4 can induce IL-8 promoter transactivation and IL-8 protein synthesis and that NF-B and AP-1 response elements were essential and sufficient for IL-8 transactivation by LTC 4 in CysLT 2 wt cells (Thompson et al., 2008) . We therefore addressed the impact of the M201V mutation on the activation of NF-B and AP-1.
In CysLT 2 wt cells, all pathways studied (p65, ERK, p38, and JNK) could be activated by LTC 4 or LTD 4 in a time-and concentration-dependent manner. The M201V mutation caused a differential modulation in the activation of these four pathways after stimulation by LTs. For LTC 4 , the activation of JNK and p65 was more affected by the mutation than the activation of ERK and p38. However, at early times (5-15 min) and higher concentrations (10 -100 nM), the mutation had essentially no effect on the activation of p65, ERK, p38, or JNK by LTC 4 . This is consistent with the results of IL-8 promoter transactivation where the polymorphism affected the response only at suboptimal concentrations of LTC 4 . In contrast, for all stimulation periods and all concentrations used, LTD 4 failed to activate p65 and JNK in CysLT 2 M201V-expressing cells. Phosphorylation of p38 was also markedly impaired, whereas phosphorylation of ERK was relatively less affected. Moreover, the activation of ERK and p38 was equivalent in both cell lines at higher LTD 4 concentrations. This is in concordance with the results of IL-8 gene activation, where the M201V mutation abolished IL-8 promoter transactivation at all concentrations of LTD 4 except the highest (100 nM). At this highest LTD 4 concentration, IL-8 promoter transactivation may have been caused by the activation of ERK and p38.
The present study has defined certain elements of CysLT 2 signaling that are impaired or lost with the M201V mutation. Because the study by Pillai et al. (2004) has shown that the polymorphism was significantly undertransmitted to asthmatics, the authors suggested that this mutation would have a protective effect in asthma. It would indicate that inhibiting CysLT 2 signaling, similar to blocking CysLT 1 signaling as is currently done with selective antagonists, would constitute a potentially useful therapeutic target against asthma. On the other hand, the study by Thompson et al. (2003) demonstrated that the polymorphism was associated with atopy. In this case, inhibiting CysLT 2 signaling could lead to enhanced allergic response and would be deemed undesirable. In a separate work, we have cotransfected CysLT 1 with either CysLT 2 wt or CysLT 2 M201V in HEK293 cells and have not found either combination to affect responses to LTC 4 or LTD 4 (S. Véronneau, unpublished observations).
Our studies raise several questions concerning the M201V mutation, including whether different G proteins are involved, whether cellular trafficking is affected, and especially what is the mechanism through which it affects LTD 4 more than LTC 4 .
In conclusion, the M201V mutation decreases the affinity of the CysLT 2 receptor for LTC 4 by 50% and radically decreases the affinity for LTD 4 . This polymorphism also affects the signaling efficiency of CysLT 2 . It affects the production of IPs, the transactivation of the IL-8 promoter, and the phosphorylation of p65, ERK, p38, and JNK. CysLT 2 responses to LTD 4 are much more affected than those to LTC 4 , with p65 and JNK signaling pathways being more affected than ERK and p38. The impact of this mutation on other elements in the physiopathology of asthma remains to be elucidated.
